Abstract: Pharmaceutically useful compounds of the following formula: ##STR1## wherein R.sub.1 represents hydrogen or hydroxy; R.sub.2 represents hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; n is a positive whole integer of from 1 to 5; R.sub.3 is --CH.sub.3, --CH.sub.2 OH, --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; and A and B are individually hydrogen or hydroxy; with the provisos that at least one of A or B is hydrogen and one of A or B is other than hydrogen when R.sub.3 is --CH.sub.3 ; and pharmaceutically acceptable acid addition salts thereof.

Abstract: A process is disclosed for preparing substituted bis-(amidinoureas) by reacting a 1-substituted-4-alkyl-4-isothiobiuret with a compound containing two aliphatic amino groups.

Abstract: Novel N,N'-bis(phenylcarbamoylalkyl)amidines having antiarrhythmic activity are disclosed. They are prepared by reacting an aminoalkanoylanilide with an active acid derivative such as an imidic acid ester or an alkyl orthoester.

Abstract: Antimicrobial compounds are disclosed having the formula:Z--B--Y--B--Zwherein B is carbamylguanidino or thiocarbamylguanidino; Y is an alkylene group which contains one to three nitrogen atoms or which contains two nitrogens as part of a cyclic structure; and Z can represent a number of groups such as alkyl, cycloalkyl, aryl and aralkyl.

Abstract: Antimicrobial compounds are disclosed having the formulaZ--B--Y--B--Zwherein B is carbamylguanidino or thiocarbamylguanidino; Y is a bivalent hydrocarbon radical which can be aliphatic, alicyclic or aromatic or a combination of aliphatic with alicyclic or aromatic; and Z can represent a number of groups such as alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkylthioalkyl or phenylthioalkyl.

Abstract: Cardiac arrhythmias can be treated by administering an effective amount of 3-aryloxy-1-(2-or 4-iminodihydro-1-pyridyl)-2-propanol or phamaceutically acceptable acid addition compound. Many new effective compounds of this type are disclosed.

Abstract: 1-[2-Hydroxy-3-(4-alkyl-1-piperazinyl)-4-oxo-2-cyclobuten-1-ylidene]-4-alky lpiperazinium hydroxide inner salts and related compounds are described herein. These compounds are useful as anti-viral agents. They are prepared from 2-anilino-3-hydroxy-4-(phenylimino)-2-cyclobuten-1-one and the appropriate monosubstituted piperazine.

Abstract: An ophthalmic solution is disclosed comprising an aqueous solution of polyvinyl alcohol, hydroxyethyl cellulose, polyvinylpyrrolidone, and, optionally, hydroxypropyl methylcellulose. The ophthalmic solution is used in treating dry eye syndrome due to insufficient tear production in humans and mammals, and as an ocular lubricant for inflamed eyes.

Abstract: Bronchial asthma and other bronchospastic and allergic diseases are treated by administering an effective amount of a substituted xanthine compound having the formula: ##STR1## wherein: R.sub.1 = C.sub.1 -C.sub.3 alkyl,R.sub.3 = c.sub.1 -c.sub.7 alkyl, C.sub.3 -C.sub.7 alkenyl, C.sub.3 -C.sub.7 alkynyl, C.sub.3 -C.sub.7 cycloalkyl or C.sub.4 -C.sub.7 cycloalkylalkyl,R.sub.8 = h, c.sub.1 -c.sub.4 alkyl, C.sub.3 -C.sub.4 alkenyl, C.sub.3 -C.sub.4 alkynyl or C.sub.3 -C.sub.4 cycloalkyl,R = c.sub.1 -c.sub.4 alkyl, 2-halo C.sub.2 -C.sub.3 alkyl, or phenylNovel and preferred bronchodilator and antiallergy compounds are disclosed having the formula ##STR2## wherein: R.sub.1 = C.sub.1 -C.sub.2 alkylR.sub.3 = ch.sub.2 --(c.sub.3 -c.sub.4 alkyl),--CH.sub.2 --(C.sub.3 -C.sub.4 alkenyl), or --CH.sub.2 --(C.sub.3 -C.sub.4 cycloalkyl)R.sub.8 = h, c.sub.1 -c.sub.2 alkyl,R = c.sub.1 -c.sub.4 alkyl, 2-halo C.sub.2 -C.sub.

Abstract: Antimicrobial compounds are disclosed having the formula:Z--B--Y--B--Z .nHAwherein B is carbamylguanidino, or thiocarbamylguanidino, Y is a bivalent organic radical selected from the group consisting of C.sub.2 -C.sub.12 alkylene, C.sub.5 -C.sub.12 cycloalkylene, C.sub.5 -C.sub.12 cycloalkylenebis(loweralkyl), C.sub.6 -C.sub.12 arylene and loweralkylarylene, C.sub.7 -C.sub.12 aryleneloweralkyl, and C.sub.8 -C.sub.12 arylenebis(loweralkyl) and Z is selected from the group consistng of C.sub.1 -C.sub.2 alkyl; C.sub.4 -C.sub.12 dialkylaminoalkyl; C.sub.3 -C.sub.12 alkenyl; C.sub.3 -C.sub.12 alkynyl; C.sub.3 -C.sub.12 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl; C.sub.1 -C.sub.10 alkoxy C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; C.sub.1 -C.sub.10 alkythio C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; phenoxy C.sub.2 -C.sub.6 alkyl; phenylthio C.sub.2 -C.sub.6 alkyl; C.sub.6 -C.sub.14 aryl; C.sub.7 -C.sub.14 aralkyl and arylcycloalkyl; and C.sub.

Abstract: Antimicrobial compounds are disclosed having the formula:Z--B--Y--B --Z .sup.. nHAwherein B is carbamylguanidino, or thiocarbamylguanidino, Y is a bivalent organic radical selected from the group consisting of C.sub.2 -C.sub.12 alkylene, C.sub.5 -C.sub.12 cycloalkylene, C.sub.5 -C.sub.12 cycloalkylenebis(loweralkyl), C.sub.6 -C.sub.12 arylene and loweralkylarylene, C.sub.7 -C.sub.12 aryleneloweralkyl, and C.sub.8 -C.sub.12 arylenebis(loweralkyl) and Z is selected from the group consisting of C.sub.1 -C.sub.12 alkyl; C.sub.4 -C.sub.12 dialkylaminoalkyl; C.sub.3 -C.sub.12 alkenyl; C.sub.3 -C.sub.12 alkynyl; C.sub.3 -C.sub.12 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl; C.sub.1 -C.sub.10 alkoxy C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; C.sub.1 -C.sub.10 alkylthio C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; phenoxy C.sub.2 -C.sub.6 alkyl; phenylthio C.sub.2 -C.sub.6 alkyl; C.sub.6 -C.sub.14 aryl; C.sub.7 -C.sub.

Abstract: Antimicrobial compounds are disclosed having the formula:Z--B--Y--B--Z .rHAwherein B is carbamylguanidino or thiocarbamylguanidino, Y is a nitrogen-containing alkylene group having the structural formula: ##STR1## WHEREIN: N = 2-4m = 2-4p = 1,2q = 2-4x = 0-3y = 0-2x = 0 when y .noteq. 0 and y = 0 when x .noteq. 0,And R is hydrogen or a C.sub.1 -C.sub.8 hydrocarbon radical selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, and aralkyl radicals, R' and R" are each hydrogen or C.sub.1 -C.sub.4 alkyl and may be the same or different and Z is selected from the group consisting of C.sub.1 -C.sub.12 alkyl, di(C.sub.1 -C.sub.10 alkylamino)-C.sub.10 -C.sub.2 having a total carbon content of C.sub.4 -C.sub.12 ; C.sub.3 -C.sub.12 alkenyl; C.sub.3 -C.sub.12 alkynyl; C.sub.3 -C.sub.12 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl; C.sub.6 -C.sub.12 cycloalkenyl, C.sub.7 -C.sub.14 cycloalkenylalkyl, C.sub.7 -C.sub.12 polycycloalkyl, C.sub.8 -C.sub.14 polycycloalkylalkyl, C.sub.7 -C.sub.

Abstract: A method for lowering intraocular pressure in mammals by administering thereto an effective amount of antazoline, i.e., 2-(N-benzylanilinomethyl)-2-imidazoline or its pharmacologically acceptable acid addition salts, preferably antazoline phosphate.

Abstract: Certain tertiary amines useful as pharmaceuticals are prepared in improved yields by condensing a cyclic secondary amine with a primary alkyl halide in an aqueous medium in the presence of an acid acceptor.

Abstract: Borohydride hydrogenations using agents of the formula M[RR'R"BH] wherein M is a metal and R, R', and R" are each organic groups, at least one of them being a secondary or tertiary alkyl group, are described herein. These compounds are active hydrogenating agents which are particularly useful because they permit steric control of the hydrogenation of carbonyl groups, they permit selective hydrogenation of functional groups or, where one of the R groups is optically active, they permit stereoselective hydrogenation.

Abstract: A new process for the preparation of 17.beta.-hydroxy-3-oxo-17.alpha.-pregn-4-ene-21-carboxylic acid .gamma.-lactone is described herein. The process makes use of androst-4-ene-3,17-dione as the starting material and 17.alpha.-ethynyl-17.beta.-hydroxyandrost-4-en-3-one as an early intermediate.

Abstract: A new process utilizing certain novel intermediates for the preparation of 17.beta.-hydroxy-3-oxo-17.alpha.-pregn-4-ene-21-carboxylic acid .gamma.-lactone is described herein. The procedure utilizes readily available and inexpensive sarsasaponin as starting material.

Abstract: 1-[2-Hydroxy-3-(4-alkyl-1-piperazinyl)-4-oxo-2-cyclobuten-1-ylidene]-4-alky lpiperazinium hydroxide inner salts and related compounds are described herein. These compounds are useful as anti-viral agents. They are prepared from 2-anilino-3-hydroxy-4-(phenylimino)-2-cyclobuten-1-one and the appropriate monosubstituted piperazine.

Abstract: 3,4-bis(4-substituted piperazinyl)-3-cyclobutene-1,2-diones and related compounds having antiviral activity are described herein. The subject compounds can be prepared by reacting 3,4-dimethoxy-3-cyclobutene-1,2-dione with the appropriate substituted piperazine.

Abstract: A stretcher trolley wherein the height and angle can be adjusted is described herein.